Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prelude Therapeutics Inc (PRLD)

Prelude Therapeutics Inc (PRLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 178,537
  • Shares Outstanding, K 62,865
  • Annual Sales, $ 7,000 K
  • Annual Income, $ -127,170 K
  • EBIT $ -121 M
  • EBITDA $ -124 M
  • 60-Month Beta 1.06
  • Price/Sales 26.40
  • Price/Cash Flow N/A
  • Price/Book 2.84

Options Overview Details

View History
  • Implied Volatility 196.00% (+2.10%)
  • Historical Volatility 125.70%
  • IV Percentile 9%
  • IV Rank 8.10%
  • IV High 1,459.02% on 04/15/25
  • IV Low 84.75% on 01/16/25
  • Expected Move (DTE 16) 0.64 (21.98%)
  • Put/Call Vol Ratio 5.47
  • Today's Volume 356
  • Volume Avg (30-Day) 158
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 1,743
  • Open Int (30-Day) 1,929
  • Expected Range 2.26 to 3.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.33
  • Number of Estimates 1
  • High Estimate -0.33
  • Low Estimate -0.33
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +13.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.29 +123.94%
on 12/03/25
3.00 -3.33%
on 12/29/25
+1.22 (+72.62%)
since 11/28/25
3-Month
1.15 +152.17%
on 10/10/25
4.22 -31.28%
on 11/03/25
+1.46 (+101.39%)
since 09/30/25
52-Week
0.61 +375.33%
on 04/09/25
4.22 -31.28%
on 11/03/25
+1.69 (+139.67%)
since 12/30/24

Most Recent Stories

More News
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track...

PRLD : 2.90 (+2.11%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prelude Therapeutics Incorporated ("Prelude" or the "Company") (NASDAQ: PRLD). Such investors...

PRLD : 2.90 (+2.11%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END

ONCY : 0.8740 (-1.48%)
IMRX : 6.58 (-2.23%)
ALXO : 1.1300 (-5.04%)
ERAS : 3.72 (+5.08%)
PRLD : 2.90 (+2.11%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and...

ONCY : 0.8740 (-1.48%)
IMRX : 6.58 (-2.23%)
ALXO : 1.1300 (-5.04%)
ERAS : 3.72 (+5.08%)
PRLD : 2.90 (+2.11%)
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing...

PRLD : 2.90 (+2.11%)
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prelude Therapeutics Incorporated (“Prelude” or “the...

PRLD : 2.90 (+2.11%)
Prelude Therapeutics Announces Strategic Business Update

Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs ...

PRLD : 2.90 (+2.11%)
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients...

INCY : 98.77 (-0.14%)
PRLD : 2.90 (+2.11%)
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced...

PRLD : 2.90 (+2.11%)
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to...

PRLD : 2.90 (+2.11%)

Business Summary

Prelude Therapeutics Incorporated is a clinical-stage precision oncology company. It is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorporated is based in Wilmington, United States....

See More

Key Turning Points

3rd Resistance Point 3.18
2nd Resistance Point 3.07
1st Resistance Point 2.98
Last Price 2.90
1st Support Level 2.78
2nd Support Level 2.67
3rd Support Level 2.58

See More

52-Week High 4.22
Last Price 2.90
Fibonacci 61.8% 2.84
Fibonacci 50% 2.42
Fibonacci 38.2% 1.99
52-Week Low 0.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar